Breast Cancer Therapeutics in Asia-Pacific Markets to 2021 - Growth Driven by Increasing Uptake of Premium Priced Biologics and Rising Prevalence

  • ID: 3627373
  • Report
  • Region: Asia Pacific
  • 171 Pages
  • GBI Research
1 of 5
APAC Breast Cancer Market Will Rise Substantially to $3.4 Billion by 2021

FEATURED COMPANIES

  • AbbVie
  • BioMarin
  • EUSA Pharma
  • Janssen Biotech
  • Novartis
  • Roche
  • MORE
Breast cancer, a malignant neoplasm, is the second-most common cancer and the most common cancer in women worldwide, accounting for 16% of all female cancers, making the disease exceedingly prevalent. In the past, breast cancer occurred less in women in Asia than women in Western countries. However, recent studies show that breast cancer is being diagnosed more frequently in women living in Asia, especially among younger women.

There have been wide-reaching changes in the breast cancer market over the past four decades, particularly in relation to the usage of targeted therapies, which has increased significantly. The marketed products landscape comprises a wide range of treatment options, including hormonal therapies, chemotherapies, combination therapies and targeted therapies.

The market is set to be driven by a number of new approvals for drugs and an increased uptake of premium targeted therapies. Nevertheless, significant unmet need remains for products that can improve overall survival rate, time to disease progression, and overall response.

Scope:

The current breast cancer market contains novel products, including Perjeta, a targeted therapy; Kadcyla, a human antibody-drug conjugate; and Halaven, a novel chemotherapeutic agent.
- What are the competitive advantages of the existing novel drugs?
- Are these targeted therapies used to the same magnitude in all the countries assessed?
- What are the factors contributing to the uptake of these drugs in each country?
With over 700 active pipeline molecules, most of the investigational drug candidates are being evaluated for the first-line or second-line treatment of advanced-stage breast cancer, featuring new combination therapies, targeted therapies, and promising immunotherapies, as well as chemotherapy drug candidates.
- Which classes of novel drugs are most prominent within the pipeline?
- Is there strong potential for the pipeline to address unmet needs within the breast cancer market?
- Which Asia-Pacific countries should expect a late launch and a lower uptake of the late-stage pipeline drugs?
Analysis of clinical trials since 2006 identified that the failure rates of breast cancer molecules were highest in Phase II (41%), with the overall attrition rate for breast cancer in development being 61%.
- How do failure rates vary by product stage of development, molecule type, and mechanism of action?
- How do other factors, such as average trial duration and trial size, influence the costs and risks associated with product development?
Over the 2014-2021 period, the value of the Asia-Pacific markets for breast cancer therapeutics is expected to increase at a compound annual growth rate of 8.5%, from $1.9 billion to over $3.4 billion.
- Which markets make the most significant contribution to the current market size?
- What are the epidemiology trends in these markets?
- Will new market entrants lead to substantial changes in annual therapy costs?
- How will different treatment usage patterns impact growth in the Asia-Pacific markets?
- What are the various trends observed in the market over the forecast period in each of the countries?
Rising breast cancer prevalence and increasing use of premium targeted therapies along with new product approvals will lead to significant market growth over the forecast period, despite generic sales erosion resulting from patent expirations.
- Will patent expirations or emerging pipeline molecules threaten the commercial success of existing drugs?
Various drivers and barriers would influence the market over the forecast period.
- What are the barriers that limit the uptake of premium-priced therapeutics in the accessed countries?
- Which factors are most likely to drive the market in these countries?

Reasons to buy

This report will enable you to -
- Understand the clinical context of breast cancer by considering symptoms, etiology, pathophysiology, epidemiology, diagnosis, and treatment options

- Identify the therapeutic strategies, products, and companies that dominate the current marketed products landscape and recognize gaps and areas of unmet need

- Identify key pipeline trends in molecule type, administration route, mechanism of action, and novelty

- Consider market opportunities and potential risks by examining trends in breast cancer clinical trial size, duration, and failure rate by stage of development, molecule type, and mechanism of action

- Recognize the late-stage pipeline molecules that have demonstrated strong therapeutic potential in breast cancer by examining clinical trial data and multi-scenario product forecast projections

- Compare treatment usage patterns, annual therapy costs, and market growth projections for the US, Canada, the UK, France, Germany, Italy, Spain and Japan

- Discover trends in licensing and co-development deals concerning breast cancer products and identify the major strategic consolidations that have shaped the commercial landscape
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AbbVie
  • BioMarin
  • EUSA Pharma
  • Janssen Biotech
  • Novartis
  • Roche
  • MORE
1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Introduction
2.1 Disease Introduction
2.2 Symptoms
2.3 Etiology
2.4 Pathophysiology
2.5 Epidemiology
2.6 Diagnosis and Classification
2.7 Prognosis and Disease Staging
2.8 Treatment Options
2.8.1 Surgery and Radiation Therapy
2.8.2 Chemotherapy
2.8.3 Hormonal Therapies
2.8.4 Targeted Therapies
2.8.5 Resistance to Pharmacological Therapies
2.9 Treatment Guidelines

3 Marketed Products
3.1 Overview
3.1.1 Herceptin (trastuzumab) - Genentech
3.1.2 Perjeta (pertuzumab) - Genentech
3.1.3 Afinitor (everolimus) - Novartis
3.1.4 Tykerb/Tyverb (lapatinib ditosylate monohydrate) - Novartis
3.1.5 Ibrance (palbociclib) - Pfizer
3.1.6 Ixempra (ixabepilone) - Bristol-Myers Squibb
3.1.7 Halaven (eribulin mesylate) - Eisai
3.1.8 Avastin (bevacizumab) - Genentech
3.1.9 Kadcyla (ado-trastuzumab emtansine) - Genentech
3.2 Marketed Products Heatmap
3.2.1 Herceptin
3.2.2 Perjeta
3.2.3 Afinitor
3.2.4 Tykerb/Tyverb
3.2.5 Ibrance
3.2.6 Ixempra
3.2.7 Halaven
3.3 Measuring the Effectiveness of Treatment
3.4 Conclusion

4 Pipeline Products
4.1 Overall Pipeline
4.1.1 Pipeline by Molecular Target
4.2 Clinical Trials
4.2.1 Failure Rate
4.2.2 Patient Enrollment and Clinical Trial Size
4.2.3 Duration
4.3 Competitive Clinical Trials Metrics Analysis

5 Promising Drug Candidates in Pipeline
5.1 Abemaciclib - Eli Lily
5.1.1 Abemaciclib Forecast
5.2 Buparlisib - Novartis
5.2.1 Buparlisib Forecast
5.3 Lynparza (olaparib) - AstraZeneca
5.3.1 Lynparza Forecast
5.4 Neratinib - Puma Biotechnology
5.4.1 Neratinib Forecast
5.5 Ribociclib - Novartis
5.5.1 Ribociclib Forecast
5.6 NeuVax (nelipepimut-S) - Galena Biopharma
5.7 Veliparib - AbbVie
5.8 Niraparib - Tesaro
5.9 Talazoparib - BioMarin
5.10 Alpelisib - Novartis
5.11 Atezolizumab - Roche
5.12 Entinostat - Syndax
5.13 Margetuximab - MacroGenics
5.14 Taselisib - Genentech
5.15 OBI-822/821 - OBI Pharma
5.16 Heat Map for Pipeline Products

6 Market Forecast to 2021
6.1 Geographical Markets
6.2 Asia-Pacific Market
6.3 India
6.3.1 Treatment Usage Patterns
6.3.2 Annual Cost of Therapy
6.3.3 Market Size
6.4 China
6.4.1 Treatment Usage Patterns
6.4.2 Annual Cost of Therapy
6.4.3 Market Size
6.5 Australia
6.5.1 Treatment Usage Patterns
6.5.2 Annual Cost of Therapy
6.5.3 Market Size
6.6 Japan
6.6.1 Treatment Usage Patterns
6.6.2 Annual Cost of Therapy
6.6.3 Market Size

7 Drivers and Barriers for the Disease Market
7.1 Drivers
7.1.1 Increased Uptake of Targeted and Combination Therapies for Breast Cancer
7.1.2 Growth and Aging of Populations to Increase the Incidence
7.1.3 Launch of Premium-Priced Products with Greater Efficacy than Existing Therapies
7.2 Barriers
7.2.1 High Level of Competition
7.2.2 Problems with the Reimbursement of Premium-Priced Therapeutics will Limit their Uptake
7.2.3 Delayed Presentation of Symptoms, Lack of Access and Awareness to Hamper Proper Treatment
7.2.4 Multiple Drugs to Lose Patent Protection in Forecast Period

8 Deals and Strategic Consolidations
8.1 Licensing Deals
8.1.1 EUSA Pharma Enters into Licensing Agreement with AVEO Pharma for Tivozanib
8.1.2 Sprint Bioscience Enters Licensing Agreement with Bayer HealthCare
8.1.3 Takeda Enters Licensing Agreement with ImmunoGen
8.1.4 Oncothyreon Enters Licensing Agreement with Array BioPharma for ONT-380
8.1.5 Halozyme Therapeutics Enters Licensing Agreement with Janssen Biotech
8.1.6 CTI BioPharma Enters Licensing Agreement with Servier for Pixuvri
8.2 Co-development Deals
8.2.1 Peregrine Pharmaceuticals and National Comprehensive Cancer Network (NCCN) Form Clinical Collaboration
8.2.2 MacroGenics Enters Agreement with Merck
8.2.3 Color Genomics Partners with University of California Health
8.2.4 Lycera Enters Co-development Agreement with Celgene
8.2.5 Roche Enters Agreement with Oryzon to Develop Epigenetics-Based Medicines
8.2.6 Tracon Enters Co-development Agreement with Santen

9 Appendix
9.1 All Pipeline Drugs by Phase of Development
9.1.1 Discovery
9.1.2 Preclinical
9.1.3 IND/CTA-filed
9.1.4 Phase I
9.1.5 Phase II
9.1.6 Phase III
9.1.7 Pre-registration
9.2 Market Forecasts to 2021
9.2.1 Asia-Pacific
9.2.2 China
9.2.3 India
9.2.4 Australia
9.2.5 Japan
9.3 Bibliography
9.4 Abbreviations
9.5 Research Methodology
9.5.1 Secondary Research
9.5.2 Marketed Product Profiles
9.5.3 Late-Stage Pipeline Candidates
9.5.4 Comparative Efficacy and Safety Heat Map for Marketed and Pipeline Products
9.5.5 Forecasting Model
9.5.6 Deals Data Analysis
9.6 Expert Panel Validation
9.7 Contact Us
9.8 Disclaimer

1.1 List of Tables
Table 1: Breast Cancer Therapeutics, Global, Tumor, Nodes and Metastasis Staging, 2010-2013
Table 2: Breast Cancer Therapeutics Market, Global, Pipeline Products, Discovery, 2015
Table 3: Breast Cancer Therapeutics Market, Global, Pipeline Products, Preclinical, 2015
Table 4: Breast Cancer Therapeutics Market, Global, Pipeline Products, IND/CTA-filed, 2015
Table 5: Breast Cancer Therapeutics Market, Global, Pipeline Products, Phase I, 2015
Table 6: Breast Cancer Therapeutics Market, Global, Pipeline Products, Phase II, 2015
Table 7: Breast Cancer Therapeutics Market, Global, Pipeline Products, Phase III, 2015
Table 8: Breast Cancer Therapeutics Market, Global, Pipeline Products, Pre-registration, 2015
Table 9: Breast Cancer Therapeutics Market, Asia-Pacific, Market Forecast, 2014-2021
Table 10: Breast Cancer Therapeutics Market, China, Market Forecast, 2014-2021
Table 11: Breast Cancer Therapeutics Market, India, Market Forecast, 2014-2021
Table 12: Breast Cancer Therapeutics Market, Australia, Market Forecast, 2014-2021
Table 13: Breast Cancer Therapeutics Market, Japan, Market Forecast, 2014-2021

1.2 List of Figures
Figure 1: Breast Cancer Therapeutics, Asia-Pacific, Age-Standardized Incidence per 100,000 population), 2012
Figure 2: Breast Cancer Therapeutics, Australia, Age-Specific Incidence Rate per 100,000 Population, 2001, 2006 and 2011
Figure 3: Breast Cancer Therapeutics, Global, Treatment Algorithm for Cancer Diagnosed at Stages I-III, 2015
Figure 4: Breast Cancer Therapeutics, Global, Treatment Algorithm for Cancer Diagnosed at Stage IV, 2015
Figure 5: Breast Cancer Therapeutics Market, Global, Heat Map
Figure 6: Breast Cancer Therapeutics Market, Global, Overview of Pipeline Products
Figure 7: Breast Cancer Therapeutics Market, Global, Molecular Target in the Pipeline
Figure 8: Breast Cancer Therapeutics Market, Global, Clinical Trial Overall Attrition Rate and Failure Rate by Phase (%), 2006-2015
Figure 9: Breast Cancer Therapeutics Market, Global, Clinical Trial Overall Attrition Rate and Failure Rate by Phase and Molecule Type (%), 2006-2015
Figure 10: Breast Cancer Therapeutics Market, Global, Clinical Trial Attrition Rate and Failure Rate by Phase and Molecular Target (%), 2006-2015
Figure 11: Breast Cancer Therapeutics Market, Global, Clinical Trial Size per Product by Molecule Type (participants), 2006-2015
Figure 12: Breast Cancer Therapeutics Market, Global, Clinical Trial Size per Individual Trial by Molecule Type (participants), 2006-2015
Figure 13: Breast Cancer Therapeutics Market, Global, Clinical Trial Size per Product by Molecular target (participants), 2006-2015
Figure 14: Breast Cancer Therapeutics Market, Global, Clinical Trial Size per Individual Trial by Molecular Target (participants), 2006-2015
Figure 15: Breast Cancer Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecule Type (months), 2006-2015
Figure 16: Breast Cancer Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecular Target (months), 2006-2015
Figure 17: Breast Cancer Therapeutics Market, Global, Comparison of Average Trial Metrics by Phase and Molecule Type
Figure 18: Breast Cancer Therapeutics Market, Global, Comparison of Average Trial Metrics by Phase and Mechanism of Action
Figure 19: Breast Cancer Therapeutics Market, Asia-Pacific, abemaciclib, Market Forecast ($m), 2018-2021
Figure 20: Breast Cancer Therapeutics Market, Asia-Pacific, buparlisib, Market Forecast ($m), 2018-2021
Figure 21: Breast Cancer Therapeutics Market, Asia-Pacific, Lynparza, Market Forecast ($m), 2018-2021
Figure 22: Breast Cancer Therapeutics Market, Asia-Pacific, neratinib, Market Forecast ($m), 2017-2021
Figure 23: Breast Cancer Therapeutics Market, Asia-Pacific, ribociclib, Market Forecast ($m), 2019-2021
Figure 24: Breast Cancer Therapeutics Market, Global, Pipeline Heat Map, 2015
Figure 25: Breast Cancer Therapeutics Market, Asia-pacific, Treatment Patterns by Number of Patients (million) and Market Size ($bn), 2014-2021
Figure 26: Breast Cancer Therapeutics Market, India, Treatment Patterns by Number of Patients (‘000), 2014-2021
Figure 27: Breast Cancer Therapeutics Market, India, Annual Cost of Therapy ($), 2014-2021
Figure 28: Breast Cancer Therapeutics Market, India, Market Size ($m), 2014-2021
Figure 29: Breast Cancer Therapeutics Market, China, Treatment Patterns by Number of Patients (‘000), 2014-2021
Figure 30: Breast Cancer Therapeutics Market, China, Annual Cost of Therapy ($), 2014-2021
Figure 31: Breast Cancer Therapeutics Market, China, Market Size ($m), 2014-2021
Figure 32: Breast Cancer Market, Australia, Treatment Usage Patterns by Number of Patients (‘000), 2014-2021
Figure 33: Breast Cancer Therapeutics Market, Australia, Annual Cost of Therapy ($), 2014-2021
Figure 34: Breast Cancer Therapeutics Market, Australia, Market Size ($m), 2014-2021
Figure 35: Breast Cancer Market, Japan, Treatment Usage Patterns by Number of Patients (‘000), 2014-2021
Figure 36: Breast Cancer Market, Japan, Annual Cost of Therapy ($), 2014-2021
Figure 37: Breast Cancer Therapeutics Market, Japan, Market Size ($m), 2014-2021
Figure 38: Breast Cancer Therapeutics Market, Global, Licensing Deals by Region, 2006-2015
Figure 39: Breast Cancer Therapeutics Market, Global, Licensing Deals by Deal Value, 2006-2015
Figure 40: Breast Cancer Therapeutics Market, Global, Number of Disclosed and Undisclosed Licensing Deals by Year, Aggregate Deal Value ($m) and Aggregate Upfront Payment Value ($m), 2006-2015
Figure 41: Breast Cancer Therapeutics Market, Global, Licensing Deals by Stage of Development, Deal Value ($m) and Upfront Payment Value ($m), 2006-2015
Figure 42: Breast Cancer Therapeutics Market, Global, Licensing Deals by Molecule Type and Stage of Development, 2006-2015
Figure 43: Breast Cancer Therapeutics Market, Global, Co-development Deals by Region, 2006-2015
Figure 44: Breast Cancer Therapeutics Market, Global, Number of Disclosed and Undisclosed Co-development Deals by Year and Value, 2006-2015
Figure 45: Breast Cancer Therapeutics Market, Global, Co-development Deals by Stage of Development, 2006-2015
Figure 46: Breast Cancer Therapeutics Market, Global, Co-development Deals by Molecular Target, 2006-2015

Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
- AVEO Pharma
- AbbVie
- Array BioPharma
- AstraZeneca
- Bayer HealthCare
- BioMarin
- CTI BioPharma
- Celgene
- Color Genomics
- EUSA Pharma
- Eli Lily
- Galena Biopharma
- Genentech
- Halozyme
- ImmunoGen
- Janssen Biotech
- Lycera
- MacroGenics
- Merck
- Novartis
- Novartis
- OBI Pharma
- Oncothyreon
- Peregrine Pharmaceuticals
- Puma Biotechnology
- Roche
- Santen
- Servier
- Sprint Bioscience
- Syndax
- Takeda
- Tesaro
- Tracon
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll